Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

ChemBioOffice 2010 Expands Leading Life Science Desktop Software Suite Further Into Biology, Including STATISTICA
ChemBioOffice 2010 is the latest release of CambridgeSoft Corporation"s full suite of integrated scientific desktop applications designed to aid individual chemists and biologists at their desktops, while also providing a shared solution benefiting scientists across an institution.
pharmacy online
High-Tech 'Smart' Face Mask Helps Hong Kong Families Combat Swine Flu
Beginning today, Hong Kong people and their children will have direct access to Filligent"s patented anti- microbial face mask, the BioMask(TM). The revolutionary mask, which traps and kills germs like H1N1 upon contact, was launched at Asia"s leading drugstore chain, Watsons, today. In addition, Hong Kong"s biggest travel agency, Hong Thai, will be providing the BioMask(TM), on a complimentary basis, to all air travelers through the end of August. Up until now, the CE-certified, specialist mask has only been available to medical and healthcare professionals. The launch and availability of the BioMask(TM) in consumer retailers and service providers is significant because, as CEO Melissa Mowbray-d"Arbela says, "The BioMask(TM) is the first "intelligent" face mask. You don"t have to be a health care worker or medical professional to use it correctly. Instead, the mask is very easy to put on, wear and dispose of properly. Thus, it"s one of the best forms of protection for ordinary people and their children during this year"s swine flu crisis."
News of the day
Hawai'i Tumor Registry To Launch "Sharing Ohana" Study To Learn How Lifestyle And Genes Influence Development And Survival Of Cancer
The Hawai"i Tumor Registry (HTR), jointly operated by the Cancer
Health Insurance

Amarillo Biosciences Reaches Enrollment Goal In Australian Influenza Phase 2 Clinical Trial

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) announced that it has reached full enrollment in a Phase 2 clinical study of the company"s oral interferon product at the University of Western Australia located in Perth. A total of 200 healthy volunteers meeting all eligibility criteria have been enrolled to 16 weeks of treatment with oral interferon or matching placebo. The double-blind clinical trial being conducted by Dr. Manfred Beilharz and colleagues is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season. Final study results are expected to be available before the end of the year. Amarillo Biosciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009